Catalyst Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapse™ (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse™ has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.
Catalyst Pharmaceuticals has raised $140M across 1 funding round on record, the most recent an undisclosed round of $140M announced in Jan 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Catalyst Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Catalyst Pharmaceuticals Funding Rounds
Catalyst Pharmaceuticals Founders and Leadership Team
Contact details for the Catalyst Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Catalyst Pharmaceuticals Funding Compared to Other Biotechnology Startups
Catalyst Pharmaceuticals' latest round of $140M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Catalyst Pharmaceuticals in Biotechnology and Coral Gables
Companies Similar to Catalyst Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Catalyst Pharmaceuticals Funding FAQs
What does Catalyst Pharmaceuticals do?
Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapse™ (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse™ has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.
How much funding has Catalyst Pharmaceuticals raised?
Catalyst Pharmaceuticals has raised $140M across 1 round on record. The most recent is an undisclosed round of $140M announced in Jan 2024.
When did Catalyst Pharmaceuticals last raise funding?
Catalyst Pharmaceuticals' most recent funding round on record is an undisclosed round of $140M, announced in Jan 2024.
Who founded Catalyst Pharmaceuticals?
FundedIQ lists Patrick J Mcenany (Founder) at Catalyst Pharmaceuticals.
Where is Catalyst Pharmaceuticals headquartered?
Catalyst Pharmaceuticals is based in Coral Gables, Florida, United States.
How many employees does Catalyst Pharmaceuticals have?
Catalyst Pharmaceuticals is in the 101-250 employee band.
How does Catalyst Pharmaceuticals' funding compare to other Biotechnology startups?
Catalyst Pharmaceuticals' latest round of $140M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Catalyst Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Catalyst Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.